Company intelligence / Profile preview

Omeza

Sarasota, Florida, United Statesomeza.com ↗

Ownership: Private
Employees: ~25
Development stage: Commercial

Overview

Omeza’s OCM™ Wound Matrix has demonstrated positive interim results in clinical trials for diabetic foot ulcers, achieving a 91% area reduction within twelve weeks and a 63% reduction within four weeks. The product is FDA-cleared via the 510(k) pathway and is being evaluated in real-world settings and additional clinical studies targeting chronic non-healing wounds of various etiologies. The company is commercial-stage with products available to healthcare providers.

Therapeutic areas: OtherDermatologyCardiovascularEndocrinology
Modalities: Drug-device combination productBiologic (marine-based peptides and omega fatty acids)Device (wound matrix)
Industry: Biotech

Drug pipeline

2 assets

Omeza Complete Matrix

Unknown

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Omeza.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Omeza.

Explore the full profile